Sangamo Therapeutics Inc (NASDAQ:SGMO) gapped up before the market opened on Wednesday . The stock had previously closed at $11.34, but opened at $11.37. Sangamo Therapeutics shares last traded at $11.53, with a volume of 77,757 shares traded.
Several research analysts have recently commented on the company. Wedbush reissued a “hold” rating and set a $11.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, November 12th. HC Wainwright assumed coverage on shares of Sangamo Therapeutics in a research report on Monday, August 26th. They set a “buy” rating and a $16.00 target price for the company. BidaskClub raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 28th. Finally, Zacks Investment Research lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $13.50.
The stock has a 50 day moving average of $9.48 and a 200 day moving average of $10.23. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.77 and a quick ratio of 4.77. The firm has a market cap of $1.30 billion, a P/E ratio of -16.54 and a beta of 2.84.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.10. Sangamo Therapeutics had a negative return on equity of 30.33% and a negative net margin of 159.12%. The firm had revenue of $21.96 million during the quarter, compared to analyst estimates of $12.16 million. During the same quarter in the previous year, the company posted ($0.13) earnings per share. The company’s revenue was down 6.8% compared to the same quarter last year. On average, research analysts predict that Sangamo Therapeutics Inc will post -1.21 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. First Manhattan Co. bought a new stake in shares of Sangamo Therapeutics in the 2nd quarter worth approximately $32,000. Steward Partners Investment Advisory LLC bought a new position in shares of Sangamo Therapeutics in the second quarter worth about $50,000. Tiverton Asset Management LLC bought a new position in shares of Sangamo Therapeutics in the second quarter worth about $79,000. Tower Research Capital LLC TRC lifted its position in shares of Sangamo Therapeutics by 1,621.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 11,170 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 10,521 shares during the last quarter. Finally, Quantitative Systematic Strategies LLC acquired a new position in shares of Sangamo Therapeutics during the 2nd quarter worth about $126,000. 70.78% of the stock is currently owned by institutional investors.
Sangamo Therapeutics Company Profile (NASDAQ:SGMO)
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Recommended Story: What is an overbought condition?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.